nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—SLC22A2—Metformin—polycystic ovary syndrome	0.249	0.535	CbGbCtD
Pramipexole—SLC22A1—Metformin—polycystic ovary syndrome	0.216	0.465	CbGbCtD
Pramipexole—Tonsillitis—Metformin—polycystic ovary syndrome	0.0094	0.064	CcSEcCtD
Pramipexole—Sinus headache—Metformin—polycystic ovary syndrome	0.00729	0.0496	CcSEcCtD
Pramipexole—Tooth abscess—Metformin—polycystic ovary syndrome	0.00569	0.0387	CcSEcCtD
Pramipexole—Emotional distress—Metformin—polycystic ovary syndrome	0.00559	0.0381	CcSEcCtD
Pramipexole—Sinus congestion—Metformin—polycystic ovary syndrome	0.00477	0.0325	CcSEcCtD
Pramipexole—Toothache—Metformin—polycystic ovary syndrome	0.0039	0.0266	CcSEcCtD
Pramipexole—Respiratory distress—Metformin—polycystic ovary syndrome	0.00374	0.0255	CcSEcCtD
Pramipexole—Upset stomach—Metformin—polycystic ovary syndrome	0.00362	0.0247	CcSEcCtD
Pramipexole—Fungal infection—Metformin—polycystic ovary syndrome	0.00308	0.0209	CcSEcCtD
Pramipexole—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00293	0.02	CcSEcCtD
Pramipexole—Accidental injury—Metformin—polycystic ovary syndrome	0.00268	0.0183	CcSEcCtD
Pramipexole—Chest discomfort—Metformin—polycystic ovary syndrome	0.00268	0.0183	CcSEcCtD
Pramipexole—Neuropathy—Metformin—polycystic ovary syndrome	0.00223	0.0152	CcSEcCtD
Pramipexole—Ear pain—Metformin—polycystic ovary syndrome	0.00202	0.0138	CcSEcCtD
Pramipexole—HTR2A—urine—polycystic ovary syndrome	0.00191	0.0788	CbGeAlD
Pramipexole—Nasal congestion—Metformin—polycystic ovary syndrome	0.00189	0.0129	CcSEcCtD
Pramipexole—Injury—Metformin—polycystic ovary syndrome	0.00188	0.0128	CcSEcCtD
Pramipexole—Renal impairment—Metformin—polycystic ovary syndrome	0.00181	0.0123	CcSEcCtD
Pramipexole—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00177	0.012	CcSEcCtD
Pramipexole—Lethargy—Metformin—polycystic ovary syndrome	0.00176	0.012	CcSEcCtD
Pramipexole—Pain in extremity—Metformin—polycystic ovary syndrome	0.00172	0.0117	CcSEcCtD
Pramipexole—Migraine—Metformin—polycystic ovary syndrome	0.0017	0.0116	CcSEcCtD
Pramipexole—Dehydration—Metformin—polycystic ovary syndrome	0.0016	0.0109	CcSEcCtD
Pramipexole—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00157	0.0107	CcSEcCtD
Pramipexole—Breast disorder—Metformin—polycystic ovary syndrome	0.00156	0.0106	CcSEcCtD
Pramipexole—Cramp muscle—Metformin—polycystic ovary syndrome	0.00155	0.0106	CcSEcCtD
Pramipexole—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00154	0.0105	CcSEcCtD
Pramipexole—Abdominal distension—Metformin—polycystic ovary syndrome	0.0015	0.0102	CcSEcCtD
Pramipexole—Influenza—Metformin—polycystic ovary syndrome	0.00149	0.0101	CcSEcCtD
Pramipexole—Pancreatitis—Metformin—polycystic ovary syndrome	0.00146	0.00995	CcSEcCtD
Pramipexole—Angina pectoris—Metformin—polycystic ovary syndrome	0.00145	0.00989	CcSEcCtD
Pramipexole—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00143	0.00973	CcSEcCtD
Pramipexole—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00138	0.00943	CcSEcCtD
Pramipexole—Infestation—Metformin—polycystic ovary syndrome	0.00133	0.00905	CcSEcCtD
Pramipexole—Drowsiness—Metformin—polycystic ovary syndrome	0.00133	0.00905	CcSEcCtD
Pramipexole—Infestation NOS—Metformin—polycystic ovary syndrome	0.00133	0.00905	CcSEcCtD
Pramipexole—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.0013	0.00887	CcSEcCtD
Pramipexole—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00126	0.00856	CcSEcCtD
Pramipexole—Bradycardia—Metformin—polycystic ovary syndrome	0.00121	0.00827	CcSEcCtD
Pramipexole—Rhinitis—Metformin—polycystic ovary syndrome	0.0012	0.00814	CcSEcCtD
Pramipexole—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00119	0.00808	CcSEcCtD
Pramipexole—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00117	0.008	CcSEcCtD
Pramipexole—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00117	0.00798	CcSEcCtD
Pramipexole—DRD5—female gonad—polycystic ovary syndrome	0.00115	0.0472	CbGeAlD
Pramipexole—Eye disorder—Metformin—polycystic ovary syndrome	0.00111	0.00759	CcSEcCtD
Pramipexole—Flushing—Metformin—polycystic ovary syndrome	0.00111	0.00754	CcSEcCtD
Pramipexole—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00111	0.00754	CcSEcCtD
Pramipexole—Angiopathy—Metformin—polycystic ovary syndrome	0.00108	0.00737	CcSEcCtD
Pramipexole—Immune system disorder—Metformin—polycystic ovary syndrome	0.00108	0.00734	CcSEcCtD
Pramipexole—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00107	0.00732	CcSEcCtD
Pramipexole—Chills—Metformin—polycystic ovary syndrome	0.00107	0.00729	CcSEcCtD
Pramipexole—DRD5—endocrine gland—polycystic ovary syndrome	0.00107	0.0439	CbGeAlD
Pramipexole—Erythema—Metformin—polycystic ovary syndrome	0.00104	0.00707	CcSEcCtD
Pramipexole—Malnutrition—Metformin—polycystic ovary syndrome	0.00104	0.00707	CcSEcCtD
Pramipexole—Flatulence—Metformin—polycystic ovary syndrome	0.00102	0.00697	CcSEcCtD
Pramipexole—Dysgeusia—Metformin—polycystic ovary syndrome	0.00102	0.00693	CcSEcCtD
Pramipexole—Muscle spasms—Metformin—polycystic ovary syndrome	0.000998	0.0068	CcSEcCtD
Pramipexole—Vision blurred—Metformin—polycystic ovary syndrome	0.000979	0.00666	CcSEcCtD
Pramipexole—Tremor—Metformin—polycystic ovary syndrome	0.000973	0.00663	CcSEcCtD
Pramipexole—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000963	0.00656	CcSEcCtD
Pramipexole—HTR2B—adrenal cortex—polycystic ovary syndrome	0.000949	0.0391	CbGeAlD
Pramipexole—Malaise—Metformin—polycystic ovary syndrome	0.000936	0.00638	CcSEcCtD
Pramipexole—Syncope—Metformin—polycystic ovary syndrome	0.000931	0.00634	CcSEcCtD
Pramipexole—Palpitations—Metformin—polycystic ovary syndrome	0.000918	0.00625	CcSEcCtD
Pramipexole—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000913	0.00622	CcSEcCtD
Pramipexole—Hypertension—Metformin—polycystic ovary syndrome	0.000896	0.00611	CcSEcCtD
Pramipexole—Chest pain—Metformin—polycystic ovary syndrome	0.000884	0.00602	CcSEcCtD
Pramipexole—Myalgia—Metformin—polycystic ovary syndrome	0.000884	0.00602	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000878	0.00598	CcSEcCtD
Pramipexole—Discomfort—Metformin—polycystic ovary syndrome	0.000873	0.00595	CcSEcCtD
Pramipexole—Oedema—Metformin—polycystic ovary syndrome	0.000847	0.00577	CcSEcCtD
Pramipexole—HTR2B—endometrium—polycystic ovary syndrome	0.000847	0.0349	CbGeAlD
Pramipexole—Infection—Metformin—polycystic ovary syndrome	0.000842	0.00573	CcSEcCtD
Pramipexole—Shock—Metformin—polycystic ovary syndrome	0.000834	0.00568	CcSEcCtD
Pramipexole—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000831	0.00566	CcSEcCtD
Pramipexole—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00083	0.00565	CcSEcCtD
Pramipexole—SLC22A1—adipose tissue—polycystic ovary syndrome	0.000828	0.0341	CbGeAlD
Pramipexole—Skin disorder—Metformin—polycystic ovary syndrome	0.000823	0.00561	CcSEcCtD
Pramipexole—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000819	0.00558	CcSEcCtD
Pramipexole—Anorexia—Metformin—polycystic ovary syndrome	0.000808	0.0055	CcSEcCtD
Pramipexole—Hypotension—Metformin—polycystic ovary syndrome	0.000792	0.00539	CcSEcCtD
Pramipexole—HTR2B—uterus—polycystic ovary syndrome	0.000781	0.0322	CbGeAlD
Pramipexole—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000772	0.00526	CcSEcCtD
Pramipexole—HTR2B—adipose tissue—polycystic ovary syndrome	0.000764	0.0315	CbGeAlD
Pramipexole—Paraesthesia—Metformin—polycystic ovary syndrome	0.000761	0.00518	CcSEcCtD
Pramipexole—Dyspnoea—Metformin—polycystic ovary syndrome	0.000755	0.00515	CcSEcCtD
Pramipexole—Somnolence—Metformin—polycystic ovary syndrome	0.000753	0.00513	CcSEcCtD
Pramipexole—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000747	0.0308	CbGeAlD
Pramipexole—Dyspepsia—Metformin—polycystic ovary syndrome	0.000746	0.00508	CcSEcCtD
Pramipexole—Decreased appetite—Metformin—polycystic ovary syndrome	0.000737	0.00502	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000732	0.00498	CcSEcCtD
Pramipexole—Fatigue—Metformin—polycystic ovary syndrome	0.000731	0.00498	CcSEcCtD
Pramipexole—Constipation—Metformin—polycystic ovary syndrome	0.000725	0.00494	CcSEcCtD
Pramipexole—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000698	0.00476	CcSEcCtD
Pramipexole—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000693	0.00472	CcSEcCtD
Pramipexole—SLC22A1—vagina—polycystic ovary syndrome	0.000689	0.0284	CbGeAlD
Pramipexole—HTR2B—adrenal gland—polycystic ovary syndrome	0.000685	0.0282	CbGeAlD
Pramipexole—Urticaria—Metformin—polycystic ovary syndrome	0.000673	0.00458	CcSEcCtD
Pramipexole—Abdominal pain—Metformin—polycystic ovary syndrome	0.00067	0.00456	CcSEcCtD
Pramipexole—ADRA2C—endometrium—polycystic ovary syndrome	0.000667	0.0275	CbGeAlD
Pramipexole—HTR1B—endocrine gland—polycystic ovary syndrome	0.000659	0.0272	CbGeAlD
Pramipexole—SLC22A1—endocrine gland—polycystic ovary syndrome	0.000644	0.0266	CbGeAlD
Pramipexole—HTR2B—vagina—polycystic ovary syndrome	0.000635	0.0262	CbGeAlD
Pramipexole—DRD2—pituitary gland—polycystic ovary syndrome	0.000621	0.0256	CbGeAlD
Pramipexole—HTR2A—embryo—polycystic ovary syndrome	0.000618	0.0255	CbGeAlD
Pramipexole—ADRA2C—uterus—polycystic ovary syndrome	0.000614	0.0253	CbGeAlD
Pramipexole—HTR1A—adrenal gland—polycystic ovary syndrome	0.000614	0.0253	CbGeAlD
Pramipexole—Asthenia—Metformin—polycystic ovary syndrome	0.000608	0.00414	CcSEcCtD
Pramipexole—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000603	0.0249	CbGeAlD
Pramipexole—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000601	0.0248	CbGeAlD
Pramipexole—Pruritus—Metformin—polycystic ovary syndrome	0.0006	0.00408	CcSEcCtD
Pramipexole—Diarrhoea—Metformin—polycystic ovary syndrome	0.00058	0.00395	CcSEcCtD
Pramipexole—Dizziness—Metformin—polycystic ovary syndrome	0.00056	0.00382	CcSEcCtD
Pramipexole—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000539	0.0222	CbGeAlD
Pramipexole—Vomiting—Metformin—polycystic ovary syndrome	0.000539	0.00367	CcSEcCtD
Pramipexole—Rash—Metformin—polycystic ovary syndrome	0.000534	0.00364	CcSEcCtD
Pramipexole—Dermatitis—Metformin—polycystic ovary syndrome	0.000534	0.00364	CcSEcCtD
Pramipexole—HTR1A—endocrine gland—polycystic ovary syndrome	0.000532	0.0219	CbGeAlD
Pramipexole—ADRA2A—endometrium—polycystic ovary syndrome	0.000532	0.0219	CbGeAlD
Pramipexole—Headache—Metformin—polycystic ovary syndrome	0.000531	0.00362	CcSEcCtD
Pramipexole—Nausea—Metformin—polycystic ovary syndrome	0.000503	0.00343	CcSEcCtD
Pramipexole—ADRA2C—female gonad—polycystic ovary syndrome	0.000503	0.0207	CbGeAlD
Pramipexole—ADRA2C—vagina—polycystic ovary syndrome	0.0005	0.0206	CbGeAlD
Pramipexole—ADRA2A—uterus—polycystic ovary syndrome	0.00049	0.0202	CbGeAlD
Pramipexole—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000482	0.0198	CbGeAlD
Pramipexole—DRD2—endocrine gland—polycystic ovary syndrome	0.000481	0.0198	CbGeAlD
Pramipexole—ADRA2A—adipose tissue—polycystic ovary syndrome	0.00048	0.0198	CbGeAlD
Pramipexole—ADRA2A—adrenal gland—polycystic ovary syndrome	0.00043	0.0177	CbGeAlD
Pramipexole—HTR2A—pituitary gland—polycystic ovary syndrome	0.000409	0.0169	CbGeAlD
Pramipexole—ADRA2A—female gonad—polycystic ovary syndrome	0.000401	0.0165	CbGeAlD
Pramipexole—ADRA2A—vagina—polycystic ovary syndrome	0.000399	0.0164	CbGeAlD
Pramipexole—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000373	0.0154	CbGeAlD
Pramipexole—HTR2A—adrenal gland—polycystic ovary syndrome	0.000366	0.0151	CbGeAlD
Pramipexole—HTR2A—vagina—polycystic ovary syndrome	0.000339	0.014	CbGeAlD
Pramipexole—HTR2A—endocrine gland—polycystic ovary syndrome	0.000317	0.0131	CbGeAlD
Pramipexole—ADRA2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.72e-05	4.73e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—POMC—polycystic ovary syndrome	1.72e-05	4.73e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IGF1—polycystic ovary syndrome	1.72e-05	4.72e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—NCOR1—polycystic ovary syndrome	1.72e-05	4.72e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT2—polycystic ovary syndrome	1.72e-05	4.72e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PRL—polycystic ovary syndrome	1.71e-05	4.71e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.71e-05	4.71e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.71e-05	4.69e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.71e-05	4.69e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	1.7e-05	4.67e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.69e-05	4.66e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.69e-05	4.64e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	1.68e-05	4.62e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—GNAS—polycystic ovary syndrome	1.68e-05	4.62e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.68e-05	4.62e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	1.67e-05	4.6e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	1.67e-05	4.59e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.67e-05	4.59e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	1.67e-05	4.59e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	1.67e-05	4.58e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.66e-05	4.57e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.66e-05	4.55e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ATF1—polycystic ovary syndrome	1.65e-05	4.55e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.65e-05	4.54e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.65e-05	4.53e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.64e-05	4.52e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.64e-05	4.49e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.63e-05	4.49e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.63e-05	4.48e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IRS2—polycystic ovary syndrome	1.63e-05	4.47e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.63e-05	4.47e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.63e-05	4.47e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NRG1—polycystic ovary syndrome	1.63e-05	4.47e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.61e-05	4.43e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.61e-05	4.42e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.61e-05	4.41e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—NCOR1—polycystic ovary syndrome	1.6e-05	4.4e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	1.6e-05	4.39e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.59e-05	4.38e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—LEP—polycystic ovary syndrome	1.59e-05	4.38e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.59e-05	4.36e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	1.58e-05	4.35e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.58e-05	4.35e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.58e-05	4.34e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—GNAS—polycystic ovary syndrome	1.57e-05	4.32e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IRS2—polycystic ovary syndrome	1.57e-05	4.31e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—LEP—polycystic ovary syndrome	1.56e-05	4.29e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.55e-05	4.27e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.55e-05	4.27e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—LEP—polycystic ovary syndrome	1.54e-05	4.22e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	1.53e-05	4.2e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—MTHFR—polycystic ovary syndrome	1.52e-05	4.17e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—CYP1A1—polycystic ovary syndrome	1.52e-05	4.17e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	1.52e-05	4.17e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.52e-05	4.17e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	1.51e-05	4.16e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	1.51e-05	4.15e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.5e-05	4.13e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.5e-05	4.12e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.5e-05	4.11e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.5e-05	4.11e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.49e-05	4.1e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	1.49e-05	4.09e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	1.49e-05	4.09e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.48e-05	4.07e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	1.48e-05	4.06e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	1.47e-05	4.04e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	1.47e-05	4.03e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—LEP—polycystic ovary syndrome	1.47e-05	4.03e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.46e-05	4.01e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.44e-05	3.97e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.44e-05	3.97e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.44e-05	3.95e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.44e-05	3.95e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.44e-05	3.95e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.43e-05	3.94e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	1.43e-05	3.92e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IRS1—polycystic ovary syndrome	1.42e-05	3.91e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.42e-05	3.9e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—MTHFR—polycystic ovary syndrome	1.42e-05	3.89e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.41e-05	3.88e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.41e-05	3.88e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	1.41e-05	3.88e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.4e-05	3.84e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IRS2—polycystic ovary syndrome	1.39e-05	3.83e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.39e-05	3.82e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—LEP—polycystic ovary syndrome	1.38e-05	3.8e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	1.37e-05	3.77e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IRS1—polycystic ovary syndrome	1.37e-05	3.76e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—POMC—polycystic ovary syndrome	1.37e-05	3.76e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.37e-05	3.76e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—LEP—polycystic ovary syndrome	1.36e-05	3.75e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—INS—polycystic ovary syndrome	1.36e-05	3.74e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.36e-05	3.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	1.36e-05	3.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	1.35e-05	3.72e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	1.34e-05	3.68e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	1.33e-05	3.66e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.33e-05	3.66e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—POMC—polycystic ovary syndrome	1.32e-05	3.62e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	1.32e-05	3.62e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	1.32e-05	3.62e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—IL6—polycystic ovary syndrome	1.31e-05	3.61e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—INS—polycystic ovary syndrome	1.31e-05	3.6e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.31e-05	3.6e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.31e-05	3.59e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.31e-05	3.59e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.29e-05	3.54e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.29e-05	3.54e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	1.29e-05	3.54e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.29e-05	3.53e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IGF1—polycystic ovary syndrome	1.27e-05	3.49e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.27e-05	3.49e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT2—polycystic ovary syndrome	1.27e-05	3.48e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.26e-05	3.46e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.26e-05	3.46e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	1.25e-05	3.44e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.25e-05	3.44e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.25e-05	3.43e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.24e-05	3.42e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.23e-05	3.39e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PPARG—polycystic ovary syndrome	1.23e-05	3.38e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	1.23e-05	3.38e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.22e-05	3.37e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.22e-05	3.36e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	1.22e-05	3.34e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—POMC—polycystic ovary syndrome	1.21e-05	3.34e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.21e-05	3.34e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.21e-05	3.33e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.21e-05	3.33e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.21e-05	3.32e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—INS—polycystic ovary syndrome	1.21e-05	3.32e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.2e-05	3.31e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	1.2e-05	3.3e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	1.2e-05	3.29e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.19e-05	3.28e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.19e-05	3.27e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	1.19e-05	3.26e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.18e-05	3.25e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	1.18e-05	3.25e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	1.18e-05	3.24e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.18e-05	3.23e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—INS—polycystic ovary syndrome	1.17e-05	3.23e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	1.17e-05	3.22e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	1.16e-05	3.2e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.15e-05	3.16e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.15e-05	3.16e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PPARG—polycystic ovary syndrome	1.15e-05	3.15e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.14e-05	3.14e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.14e-05	3.14e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.14e-05	3.12e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—POMC—polycystic ovary syndrome	1.13e-05	3.11e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	1.13e-05	3.1e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	1.13e-05	3.09e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—INS—polycystic ovary syndrome	1.13e-05	3.09e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.12e-05	3.09e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.11e-05	3.06e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.1e-05	3.02e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.08e-05	2.98e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.07e-05	2.94e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.07e-05	2.93e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.06e-05	2.91e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.06e-05	2.91e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.05e-05	2.9e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	1.05e-05	2.89e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.05e-05	2.88e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	1.04e-05	2.87e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	1.03e-05	2.82e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.03e-05	2.82e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	1.02e-05	2.81e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.02e-05	2.8e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.02e-05	2.79e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	1.02e-05	2.79e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	1.02e-05	2.79e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	1.01e-05	2.78e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	1.01e-05	2.77e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	9.88e-06	2.71e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	9.86e-06	2.71e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	9.82e-06	2.7e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	9.82e-06	2.7e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	9.81e-06	2.7e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	9.77e-06	2.68e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	9.76e-06	2.68e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	9.73e-06	2.67e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	9.7e-06	2.67e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.66e-06	2.65e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	9.6e-06	2.64e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	9.54e-06	2.62e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—INS—polycystic ovary syndrome	9.54e-06	2.62e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	9.5e-06	2.61e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	9.49e-06	2.61e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	9.34e-06	2.57e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.32e-06	2.56e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	9.31e-06	2.56e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.28e-06	2.55e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	9.26e-06	2.54e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	9.16e-06	2.52e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.02e-06	2.48e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	8.96e-06	2.46e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	8.91e-06	2.45e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	8.82e-06	2.42e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	8.77e-06	2.41e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	8.73e-06	2.4e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	8.62e-06	2.37e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	8.62e-06	2.37e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	8.62e-06	2.37e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.6e-06	2.36e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	8.48e-06	2.33e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	8.48e-06	2.33e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.42e-06	2.31e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	8.33e-06	2.29e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.29e-06	2.28e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.19e-06	2.25e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.06e-06	2.21e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	8.02e-06	2.21e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	7.98e-06	2.19e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.91e-06	2.17e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	7.78e-06	2.14e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—polycystic ovary syndrome	7.76e-06	2.13e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	7.72e-06	2.12e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	7.71e-06	2.12e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	7.51e-06	2.06e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	7.47e-06	2.05e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.46e-06	2.05e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.36e-06	2.02e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.33e-06	2.01e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	7.27e-06	2e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.64e-06	1.83e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	6.59e-06	1.81e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	6.49e-06	1.78e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.41e-06	1.76e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.38e-06	1.75e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.21e-06	1.71e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	5.95e-06	1.63e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	5.9e-06	1.62e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	5.82e-06	1.6e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	5.73e-06	1.57e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.63e-06	1.55e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.54e-06	1.52e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	5.47e-06	1.5e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	5.16e-06	1.42e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	5.09e-06	1.4e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.04e-06	1.39e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	4.6e-06	1.26e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	4.44e-06	1.22e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	4.41e-06	1.21e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	4.29e-06	1.18e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	3.89e-06	1.07e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	3.83e-06	1.05e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	3.49e-06	9.58e-06	CbGpPWpGaD
